We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

2 hedge funds and large institutions have $51K invested in Loncar China BioPharma ETF in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

410% more capital invested

Capital invested by funds: $10K → $51K (+$41K)

100% more funds holding

Funds holding: 1 → 2 (+1)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

Holders
2
Holders Change
+1
Holders Change %
+100%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$41.4K
2
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$13.5K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$10K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$38K +$41.4K +2,000 New
PNC Financial Services Group
2
PNC Financial Services Group
Pennsylvania
$13K +$13.5K +652 New
UBS Group
3
UBS Group
Switzerland
– -$10K -436 Closed

CHNA Hedge Fund Activity: Q4 2018 in Review

2 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q4 2018, worth a combined $51K — up 410% from $10K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new CHNA positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Morgan Stanley, opening a new position worth an estimated $41.4K. The largest seller was UBS Group, exiting entirely with an estimated $10K sold.

  • 2 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q4 2018, up from 1 in Q3 2018.
  • Funds reported $51K of Loncar China BioPharma ETF stock for Q4 2018, up 410% quarter-over-quarter.
  • 2 funds opened new Loncar China BioPharma ETF positions in Q4 2018 and 1 closed out, a net change of +1 holder.
  • The largest Loncar China BioPharma ETF buyer in Q4 2018 was Morgan Stanley, an estimated $41.4K added.
  • The largest Loncar China BioPharma ETF seller in Q4 2018 was UBS Group, an estimated $10K sold.

Based on aggregated 13F filings for Q4 2018.